Results 51 to 60 of about 9,243 (198)

Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitations [PDF]

, 2019
Background Recruitment to clinical trials can be challenging. Methods that improve the efficiency of trial recruitment are needed to increase successful study completions.
Flynn, Robert, MacDonald, Thomas, Mackenzie, Isla, Rogers, Amy   +3 more
core   +4 more sources

Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, EarlyView.
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death. [PDF]

, 2015
Leydig cells are crucial to the production of testosterone in males. It is unknown if the cancer chemotherapeutic drug, 6-mercaptopurine (6 MP), produces Leydig cell failure among adult survivors of childhood acute lymphoblastic leukemia. Moreover, it is
Bao, Ju, Chemaitilly, Wassim, Frase, Sharon, Green, Daniel M, Janke, Laura, Lynch, John, Morgan, Jessica A, Opferman, Joseph T, Panetta, John C, Schuetz, John D, Wang, Yao, Zheng, Jie   +11 more
core   +1 more source

Long‐Term Opioids in Gout: A Matched Cohort Study From the Veterans Health Administration

Arthritis Care &Research, EarlyView.
Objective Though used frequently to treat flare, risk of long‐term opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed long‐term opioids over time.
Lindsay N. Helget, Bryant R. England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R. O'Dell, Joshua F. Baker, Ted R. Mikuls   +7 more
wiley   +1 more source

Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to investigate the cost‐effectiveness of low‐dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the “start‐low go‐slow” approach. Methods Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate‐lowering therapy and with serum urate
Yana Pryymachenko, Ross Wilson, Nicola Dalbeth, J. Haxby Abbott, Lisa Stamp   +4 more
wiley   +1 more source

Pharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male Volunteers.

PLoS ONE, 2016
UnlabelledThe present study aimed to investigate the pharmacokinetic properties of febuxostat in healthy Chinese male volunteers and evaluate whether the two formulations of febuxostat 40-mg and 80-mg tablets are bioequivalent.
Zhu Luo, Feng Nan, Jia Miao, Zhihui Chen, Mei Li, Maozhi Liang   +5 more
doaj   +1 more source

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. [PDF]

, 2019
ObjectiveLesinurad (LESU) is a selective urate reabsorption inhibitor approved at 200 mg daily for use with a xanthine oxidase inhibitor (XOI) to treat hyperuricaemia in gout patients failing to achieve target serum urate on XOI. The aim of the study was
Baumgartner, Scott, Goldfarb, David S, Jalal, Diana, Pillinger, Michael, Saag, Kenneth G, Schechter, Bruce M, Terkeltaub, Robert, Valiyil, Ritu, White, William B   +8 more
core   +1 more source

Gout - a guide for the general and acute physicians. [PDF]

, 2017
Gout is the most prevalent inflammatory arthritis and affects 2.5% of the general population in the UK. It is also the only arthritis that has the potential to be cured with safe, inexpensive and well tolerated urate-lowering treatments, which reduce ...
Abhishek, A, Doherty, M, Roddy, E
core   +1 more source

African American patients with gout: efficacy and safety of febuxostat vs allopurinol

BMC Musculoskeletal Disorders, 2012
Background African Americans are twice as likely as Caucasians to develop gout, but they are less likely to be treated with urate-lowering therapy (ULT).
Wells Alvin F, MacDonald Patricia A, Chefo Solomon, Jackson Robert L   +3 more
doaj   +1 more source

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study

Scientific Reports, 2022
Attribute-based medicine is essential for patient-centered medicine. To date, the groups of patients with chronic kidney disease (CKD) requiring urate-lowering therapy are clinically unknown.
Hiroshi Kataoka, Toshio Mochizuki, Mamiko Ohara, Yuki Tsuruta, Naomi Iwasa, Rie Yoshida, Ken Tsuchiya, Kosaku Nitta, Kenjiro Kimura, Tatsuo Hosoya, the FEATHER Investigators   +10 more
doaj   +1 more source